The abstract is read at the publisher; the summary is JClub's.
Antigen-scaffold expansion of CRISPR-Cas9-engineered TCR T cells and anti-CD19 CAR T cells yields an average 69% (±22%) antigen-specific T cells after 14 days.
- Why it matters: Manufacturing engineered T cells is resource intensive and often produces highly differentiated, exhausted products, limiting potency and durability.
- What they did: The study used antigen-scaffold technology presenting cognate antigen with stimulatory cytokines to expand engineered TCR T cells using pMHC and CAR T cells using CD19, then assessed cytotoxicity, proliferation, rechallenge, and in vivo tumor control versus IL2/7/15-expanded cells.
- The result: Ag-scaffold-expanded T cells showed enhanced cytotoxicity and sustained control upon repeated rechallenges, and in vivo improved tumor control in lymphoma and solid tumor xenograft models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.